July 2025

Ixekizumab and malignant neoplasms A pooled analysis of data from 25 randomized clinical trials

Merola et al. JAMA Dermatol 2025; 9:e252056

Merola et al. showed that the safety profile of ixekizumab (IXE) supports its long-term use in patients with PsO, PsA, or axSpA, without an increased risk for malignant neoplasm development. Merola et al. investigated the incidence rates of malignant neoplasms among patients with PsO, PsA, or axSpA who underwent long-term treatment with IXE, an IL- 17A antagonist.

Keywords:

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Ann Rheum Dis 2025;25:01024-6 doi: 10.1016/j.ard.2025.05.014

Schaefer et al. showed that treatment with JAKis (predominantly BARI and TOF) was associated with an increased HR of malignancies compared to treatment with bDMARDs in the overall study cohort, consistent with results from the ORAL surveillance trial. To better understand the complex role of JAKis in cancer development in RA patients, Schaefer et al. estimated the effects of JAKis compared to bDMARDs on the risk of malignancy (excluding NMSC) in patients with RA.

Keywords:

April 2025

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

RMD Open. 2025;11:e005026. doi: 10.1136/rmdopen-2024-005026.

Mease et al. found that bimekizumab demonstrated a favourable long-term safety profile in patients with axSpA and PsA.

Keywords:

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

RMD Open. 2025;11:e005033. doi: 10.1136/rmdopen-2024-005033.

Mariette et al. investigated the long-term safety of filgotinib with regard to MACE, VTE and malignancy across RA and UC clinical trial populations. Rates of these events remained low overall, with some increases observed in patients aged 65 years and older.

Keywords:

March 2025

Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis

Clin. Ther. 2025;47:293–297 doi: 10.1016/j.clinthera.2025.01.005

Zhao et al. found that among patients with PsA or axSpA, JAKi were not associated with increased risk of CVD or common cancers compared to TNFi or IL-17i.

Keywords:

December 2023

Malignidades nos ensaios clínicos com upadacitinibe em artrite reumatoide, artrite psoriática, espondilite anquilosante e espondiloartrite axial não radiográfica

Rheumatol Ther 2023;11(1):97–112 doi 10.1007/s40744-023-00621-6

Rates of malignancy were similar between upadacitinib, adalimumab, and MTX. They were also consistent across RA, PsA, AS and nr-axSpA. A dose-dependent increased rate of NMSC was observed with upadacitinib in RA. For RA and PsA, being older (≥65 years) and male was associated with
an increased risk of malignancy excluding NMSC.

Keywords:

September 2023

The Risk and Predictors of Malignancies in Ankylosing Spondylitis Patients in Israel—A Retrospective Electronic Data-Based Study

J Clin Med. 2023;12(15):5153 doi: 10.3390/jcm12155153

Findings from a retrospective electronic data-based study, assessing risk of overall and site-specific malignancies for AS patients in Israel, emphasize the importance of maintaining the routine observation of patients with AS to identify the early development of cancer.

Keywords:

June 2023

Inibidores de JAK e o risco de malignidades: Uma meta-análise com as indicações de tratamento

Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049

The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.

Keywords:

March 2023

Segurança de Baricitinib para Eventos de Interesse Especial em Populações em Risco: Uma análise de dados de ensaios randomizados em indicações reumatológicas e dermatológicas

Adv Ther. 2023;40(4):1867–1883 doi: 10.1007/s12325-023-02445-w

Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.

Keywords:

Risco de malignidade com tofacitinibe versus inibidores de TNF na artrite reumatoide: Resultados do Estudo Open-Label, Randomizado e Controlado ORAL Surveillance

Ann Rheum Dis. 2023;82(3):331–343 doi: 10.1136/ard-2022-222543

Results from the open-label, randomised controlled ORAL Surveillance trial find increased risk of malignancies with tofacitinib versus TNFi, highlighting the highest incidence in patients with a history of atherosclerotic cardiovascular disease or increasing cardiovascular risk.

Keywords: